{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:15:05Z","timestamp":1788387305362,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":2320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1093\/annonc\/mdt058","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T20:40:56Z","timestamp":1362084056000},"page":"1879-1886","source":"Crossref","is-referenced-by-count":68,"title":["Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group"],"prefix":"10.1016","volume":"24","author":[{"given":"T.","family":"W\u00e4sterlid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jerkeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt058_bb0010","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Dalla-Favera","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdt058_bb0015","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.3109\/10428194.2011.593274","article-title":"Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study","volume":"52","author":"Wasterlid","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdt058_bb0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00001622-200409000-00003","article-title":"Treatment advances in adult Burkitt lymphoma and leukemia","volume":"16","author":"Kasamon","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3816\/CLM.2009.n.060","article-title":"Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens","volume":"9","author":"Kelly","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdt058_bb0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/asheducation-2008.1.341","article-title":"Burkitt lymphoma in adults","author":"Perkins","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1093\/annonc\/mdt058_bb0035","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol","volume":"16","author":"Divine","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0040","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt058_bb0045","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0050","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0055","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/0959-8049(92)90235-T","article-title":"Treatment of poor prognosis Burkitt's lymphoma in adults with the Societe Francaise d'Oncologie Pediatrique LMB Protocol\u2014a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC)","volume":"28A","author":"Philip","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdt058_bb0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2011.08877.x","article-title":"Burkitt lymphoma in adults","volume":"156","author":"Linch","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt058_bb0065","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt058_bb0070","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt's\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0075","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdt058_bb0080","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt058_bb0085","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664","article-title":"Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols","volume":"85","author":"Soussain","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt058_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdt058_bb0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2141.2004.05141.x","article-title":"High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults","volume":"126","author":"Di Nicola","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt058_bb0100","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","article-title":"Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0105","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt058_bb0110","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdt058_bb0115","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","article-title":"Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas","volume":"8","author":"Fayad","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1093\/annonc\/mdt058_bb0120","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s12185-010-0728-0","volume":"92","author":"Maruyama","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdt058_bb0125","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the addition of rituximab to CODOX-M\/IVAC for Burkitt's lymphoma: a retrospective analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2141.2010.08447.x","article-title":"Rituximab in combination with CODOX-M\/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%","volume":"152","author":"Mohamedbhai","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdt058_bb0135","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.3109\/10428194.2011.587560","article-title":"Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry","volume":"52","author":"Abrahamsson","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdt058_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdr058","article-title":"R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group","volume":"23","author":"Gang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0145","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt058_bb0150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2141.2011.08947.x","article-title":"RD-CODOX-M\/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and \u2018unclassifiable\u2019 highly aggressive B-cell lymphoma","volume":"156","author":"Corazzelli","year":"2012","journal-title":"Br J Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419366426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/7\/1879\/466382\/mdt058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:37:42Z","timestamp":1624693062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419366426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0923753419366426"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt058","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}